Citation

BibTex format

@article{Wu:2024:10.1016/S2213-2600(23)00432-0,
author = {Wu, Z and Spencer, LG and Banya, W and Westoby, J and Tudor, VA and Rivera-Ortega, P and Chaudhuri, N and Jakupovic, I and Patel, B and Thillai, M and West, A and Wijsenbeek, M and Maher, TM and Smith, JA and Molyneaux, PL},
doi = {10.1016/S2213-2600(23)00432-0},
journal = {The Lancet Respiratory Medicine},
pages = {273--280},
title = {Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial},
url = {http://dx.doi.org/10.1016/S2213-2600(23)00432-0},
volume = {12},
year = {2024}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BackgroundIdiopathic pulmonary fibrosis is a progressive fibrotic lung disease, with most patients reporting cough. Currently, there are no proven treatments. We examined the use of low dose controlled-release morphine compared with placebo as an antitussive therapy in individuals with idiopathic pulmonary fibrosis.MethodsThe PACIFY COUGH study is a phase 2, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial done in three specialist centres in the UK. Eligible patients aged 40–90 years had a diagnosis of idiopathic pulmonary fibrosis within 5 years, self-reported cough (lasting >8 weeks), and a cough visual analogue scale (VAS) score of 30 mm or higher. Patients were randomly assigned (1:1) to placebo twice daily or controlled-release morphine 5 mg orally twice daily for 14 days followed by crossover after a 7-day washout period. Patients were randomised sequentially to a sequence group defining the order in which morphine and placebo were to be given, according to a computer-generated schedule. Patients, investigators, study nurses, and pharmacy personnel were masked to treatment allocation. The primary endpoint was percentage change in objective awake cough frequency (coughs per h) from baseline as assessed by objective digital cough monitoring at day 14 of treatment in the intention-to-treat population, which included all randomised participants. Safety data were summarised for all patients who took at least one study drug and did not withdraw consent. This study was registered at ClinicalTrials.gov, NCT04429516, and has been completed.FindingsBetween Dec 17, 2020, and March 21, 2023, 47 participants were assessed for eligibility and 44 were enrolled and randomly allocated to treatment. Mean age was 71 (SD 7·4) years, and 31 (70%) of 44 participants were male and 13 (30%) were female. Lung function was moderately impaired; mean forced vital capacity (FVC) was 2·7 L (SD 0·76), mean predicted FVC was 82%
AU - Wu,Z
AU - Spencer,LG
AU - Banya,W
AU - Westoby,J
AU - Tudor,VA
AU - Rivera-Ortega,P
AU - Chaudhuri,N
AU - Jakupovic,I
AU - Patel,B
AU - Thillai,M
AU - West,A
AU - Wijsenbeek,M
AU - Maher,TM
AU - Smith,JA
AU - Molyneaux,PL
DO - 10.1016/S2213-2600(23)00432-0
EP - 280
PY - 2024///
SN - 2213-2600
SP - 273
TI - Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial
T2 - The Lancet Respiratory Medicine
UR - http://dx.doi.org/10.1016/S2213-2600(23)00432-0
UR - https://www.ncbi.nlm.nih.gov/pubmed/38237620
UR - https://www.sciencedirect.com/science/article/pii/S2213260023004320
UR - http://hdl.handle.net/10044/1/109009
VL - 12
ER -